Urokinase and tissue type plasminogen activators and their type 1 inhibitor (PAI-1) in gastric cancer

Voprosy Onkologii

Volumn 49, Issue 2, 2003, Pages 165-169

  Gerstein, Ye S ^a   Sherbakov, A M ^a   Kazmin, A I ^b   Ognerubov, N A ^b   Kushlinsky, N Ye ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^b VORONEZH STATE MEDICAL UNIVERSITY NAMED AFTER N N BURDENKO   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER PATIENT; ENZYME IMMUNOASSAY; HISTOPATHOLOGY; HUMAN; PLASMINOGEN ACTIVATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STOMACH CARCINOMA; STOMACH MUCOSA; TISSUE SECTION; ADOLESCENT; ADULT; AGE; AGED; CHEMISTRY; CYTOSOL; ENZYMOLOGY; FEMALE; IMMUNOASSAY; MALE; MIDDLE AGED; STOMACH TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CYTOSOL; FEMALE; GASTRIC MUCOSA; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; STOMACH NEOPLASMS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037530308     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Allgayer H., Babic R., Grutzner K.U. et al. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns // Clin. Exp. Metastasis. - 1998. - Vol. 16. - P. 62-73.
2. Andreasen P.A., Georg B., Lund L.R. et al. Plasminogen activator inhibitors: hormonally regulated serpins // Mol. Cell. Endocrinol. - 1990. - Vol. 68. - P. 1-19.
3. Bell W.R. The fibrinolytic system in neoplasia // Semin. Thromb. Hemost. - 1996 - Vol. 22. - P. 459-478.
4. Cho J.Y., Chung H.C., Noh S.H. et al. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma // Cancer (Philad.). - 1997. - Vol. 79. - P. 878-883.
5. Choi Y.K., Yoon B.I., Kook Y.H. et al. Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice // Jpn. J. Cancer Res. - 2002. - Vol. 93. - P. 151-156.
6. Ganesh S., Sier C.F., Heerding M.M. et al. Prognostic value of the plasminogen activation system in patients with gastric carcinoma // Cancer (Philad.). - 1996. - Vol. 77. - P. 1035-1043.
7. Grebenschikov N., Geurts-Moespot A., De Witte H. et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols // Int. J. Biol. Markers. - 1997. - Vol. 12. - P. 6-14.
8. Look M.P., Foekens J.A. Clinical relevance of the urokinase plasminogen activator system in breast cancer // APMIS. - 1999. - Vol. 107. - P. 150-159.
9. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion // Physiol. Rev. - 1993. - Vol. 73. - P. 161-195.
10. Okusa Y., Ichikura T., Mochizuki H., Shinomiya N. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines // Int. J. Oncol. - 2000. - Vol. 17. - P. 1001-1005.
11. Plebani M., Herszenyi L., Cardin R. et al. Cystein and serin proteases in gastric cancer // Cancer (Philad.). - 1995. - Vol. 76. - P. 367-375.
12. Sier C.F., Verspaget H.W., Griffioen G. et al. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach // Gut. - 1993. - Vol. 34. - P. 80-85.
13. Umehara Y., Kimura T., Yoshida M. et al. Relationship between plasminogen activators and stomach carcinoma stage // Acta Oncol. - 1991. - Vol. 30. - P. 815-818.